Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic Impairment
P. Khaykin,P. Kotzerke,C. Stephan,G. Nisius,M. Bickel,A. Haberl,M. Stürmer,M. Kurowski,R. Brodt,N. von Hentig
DOI: https://doi.org/10.1097/FTD.0b013e3182a28c6a
2014-04-01
Therapeutic Drug Monitoring
Abstract:Objective: Lopinavir/ritonavir plus nucleoside reverse transcriptase inhibitors is one standard antiretroviral therapy regimen, both in patients with HIV alone and coinfected with hepatitis B or C. Our objective was to investigate whether hepatitis coinfection without clinical signs of hepatic impairment is a cofactor altering lopinavir pharmacokinetics and influencing therapy outcome. Methods: Steady-state 12-hour pharmacokinetic profiles of lopinavir/ritonavir were assessed in patients with (group 1, n = 20) or without (group 2, n = 36) hepatitis coinfection, taking lopinavir/ritonavir 400/100 mg twice a day plus nucleoside reverse transcriptase inhibitors, measured by means of high-performance liquid chromatography-tandem mass spectrometry. Demographic (sex, age, weight), pharmacological (formulation, comedication), clinical, and virological/immunologic parameters (HIV-RNA PCR, CD4+ cell count) were compared between the groups and included in regression analyses for correlations with lopinavir pharmacokinetic parameters (Cmin, Cmax, AUC, CL, and t1/2) and viral load evolution over 48 weeks on therapy. Patient pairs were matched 1:2 for the parameters sex, age, weight, ethnicity, and drug formulation. Results: None of the hepatitis-related cofactors (aspartate aminotransferase, alanine aminotransferase, &ggr;GT, HBe Ag, HBsAg, HCV-RNA PCR, HCV-therapy) had an influence on lopinavir pharmacokinetics in this group of patients. Lopinavir Cmin (P = 0.039) and area under the curve (P = 0.038) and ritonavir Cmax (P = 0.049) were significantly enhanced in hepatitis-coinfected patients, but correlated only with drug formulation (ie, soft gel capsule or Meltrex tablet formulation, multivariate regression analysis, P = 0.001), not hepatitis coinfection. Conclusions: Despite moderately enhanced lopinavir/ritonavir plasma concentrations, regular therapeutic drug monitoring is not to be considered in hepatitis-coinfected patients without hepatic impairment. Antiviral efficacy is comparable between both groups, a less-pronounced CD4+ cell increase in hepatitis-coinfected patients is in line with previously published data.